Kornimate/medical-research-clean huggingface dataset:
lumbar spinal stenosis and central sensitization

Conditions: Lumbar Spinal Stenosis

Summary: lumbar spinal stenosis (lss) functionally limits individuals by causing pain in both the waist and the legs during activity and walking. pain is, therefore, an important problem for patients. pain lasts for years in lss and thus becomes chronically persistent. as a result, persistent pain can cause sensitization due to a decrease in the pain threshold. this condition affects patients not only biomedically but also biopsychosocially. for this reason, various sleep disorders and mood disorders can develop in patients. therefore, this study aimed to examine the relationship between central sensitization and pain, disability, sleep and depression in patients with lss.

lumbar spinal stenosis (lss) functionally limits individuals by causing pain in both the waist and the legs during activity and walking. in particular, the pain in lss lasts for years and becomes chronic and can cause persistent and disturbing sensitization. this situation may be associated with decreased pain threshold and allodynia. various studies show that sensitization can affect individuals biomedically and may lead to important health problems. some of these are sleep and depression problems. sleep and a healthy mentality are important for continuing daily activities and preserving quality of life. however, when the literature is examined, it is seen that central sensitization and the parameters that may be related to this have not been examined sufficiently. therefore, the aim of this study is to examine the relationship between central sensitization and pain, disability, sleep and depression in patients with lss.

Eligibility criteria:
inclusion criteria: * diagnosed with lumbar spinal stenosis by mri, * the ages of 45-80, * low back and/or leg pain that has persisted for at least 3 months * volunteer to participate in the study exclusion criteria: * patients who did not agree to participate in the study, * those with a history of serious neurological diseases such as parkinson's, hemiplegia, multiple sclerosis, * those who had undergone surgery in the lumbar region within the last year, * those with advanced joint disease in the lower extremity, * those with malignancy in the spine, * those who had a previous operation for the lower extremity, * those who had a pain or disability in other musculoskeletal joints, * those who had a psychological disorder or peripheral vascular disease * those who had any concurrent serious medical condition, including sepsis or cancer * those who did not cooperate well were not included in the study.
a prospective pilot study to evaluate the diagnostic performance of a wireless sensor capsule in detection of ugib

Conditions: UGI Bleed

Summary: it is a single-center, prospective study, which will be conducted in a tertiary academic hospital (prince of wales hospital). all subjects will undergo a paired examination of hemopill® acute capsule and oesophago-gastro-duodenoscopy (ogd).

it is a single-center, prospective study, which will be conducted in a tertiary academic hospital (prince of wales hospital). all subjects will undergo a paired examination of hemopill® acute capsule and oesophago-gastro-duodenoscopy (ogd).

Eligibility criteria:
inclusion criteria: subjects are eligible if: * they have symptoms and signs of suspected ugib (melena, per rectal bleeding, coffee ground vomiting, history of hematemesis); * they will undergo ogd within 24 hours; * written consent obtained. exclusion criteria: subjects will be excluded from the study if they have any of the followings: * contraindications for ogd (e.g. respiratory failure, suspected perforation); * contraindications for capsule endoscopy (e.g. known gastrointestinal obstruction or stricture, severe dysphagia, impaired consciousness); * cardiac pacemaker or implanted electromedical devices; * history of gastrectomy or bowel resection; * active ongoing fresh hematemesis; * unstable hemodynamics despite adequate resuscitation; * advanced comorbidities (defined as american society of anesthesiologists grade 4 or above); * pregnancy.
radiofrequency ablation of ectopic atrial tachycardia

Conditions: Congenital Disorders

Summary: a retrospective chart review will be performed on 50 patients who received rfa for the treatment of eat between august 1992 and august 2003 at children's healthcare of atlanta. the use of the carto/biosense catheter has improved outcomes with decreased radiation exposure to patients.

ectopic atrial tachycardia (eat) is a relatively rare arrhythmia in the pediatric population. it is defined by a run of more than 3 premature atrial contractions together. in eat, the arrhythmia tends to increase in rate over a period of time and then slows down gradually to a normal rhythm. ectopic atrial tachycardia (eat) is mostly encountered in patients with structurally normal hearts however, occasionally physicians do observe this type of disorder in children following surgery for congenital heart defects. current reports suggest that eat occurs in approximately 1 in 10,000 children (hamilton, 2002). children with eat usually present with a multitude of symptoms. the most common symptoms associated with pediatric eat are palpitations, chest pain, lightheadedness, presyncope, and dyspnea. other symptoms can include exercise intolerance and congestive heart failure. these are usually late manifestations. in the patients with tachycardia induced cm, the time of development of cm is dependent on the rate and duration of the tachycardia however, in most cases, dilation is present upon diagnosis. this cm can be reversed with successful treatment of the arrhythmia. the treatment for chronic eat includes medications such as adenosine and for difficult to control cases, radiofrequency ablation (rfa). rf ablation has been successful in curing eat, with success rates ranging from 75-100%. it has been shown that the complication rates are similar to other rf ablation procedures, with a higher risk of recurrence (hamilton, 2002). at children's healthcare of atlanta, the cardiac catheterization lab performs approximately 10 radiofrequency ablations for eat each year. the goal of this retrospective review is to assess the frequency of recurrence of the eat among a subset of patients receiving treatment between august 1992 - august 2003

Eligibility criteria:
inclusion criteria: * 50 patients who received rfa for treatment of eat between august 2992 and august 2003 * treatment at children's healthcare of atlanta exclusion criteria: * those who do not meet inclusion criteria

Keywords: pediatric cardiac radiofrequency ablation ectopic atrial tachycardia
a diagnostic nomogram for predicting vaginal invasion in cervical cancer

Conditions: Cervix Carcinoma

Summary: this study aims to develop a diagnostic nomogram based on clinical factors with the prediction values of vaginal invasion in cervical cancer to optimize the treatment plan and surgical procedures.

vaginal invasion is a crucial index participant in cervical cancer tumor staging and prognosis prediction. however, the roles of vaginal invasion are overlooked in the literature, compared with those of lymph node metastasis and parametrial invasion. as far as we know, this study is novel to construct a nomogram to predict the probability of pathologic vaginal invasion occurrence.

Eligibility criteria:
inclusion criteria: * pathologically confirmed cervical cancer; * figo2018 stage ib-iia according to the result of physical examination and images; * no preoperative treatment before surgery; * abdominal mri is performed within three weeks before surgery. blood routine, biochemistry, blood tumor markers and coagulation function were examined within 1 week before surgery. * all patients undergo radical hysterectomy (rh) with bilateral pelvic lymphadenectomy or paraaortic lymph node dissection. exclusion criteria: * accompanied with other tumors; * accompanied with chronic infectious and immune diseases; * incomplete clinical data.
online videodensitometric assessment of aortic regurgitation in the cath-lab

Conditions: Aortic Valve Insufficiency; Heart Valve Diseases; Regurgitation, Aortic; Paravalvular Aortic Regurgitation

Summary: following the high feasibility of analyses by core laboratory with videodensitometry determined in the assess-regurge registry, this is an early clinical feasibility study of online videodensitometric assessment of aortograms to quantitate aortic regurgitation (ar) in the cath lab, specifically in the setting of transcatheter aortic valve replacement (tavr)

oval (online videodensitometric assessment of aortic regurgitation in the cath-lab) is a single centre, prospective, proof-of-principle, feasibility study performed in the academic medical centre (amsterdam). one hundred consecutive patients with aortic stenosis and indication to undergo tavr by the institution's heart team are being enrolled in oval. all final aortograms will be performed according to predetermined acquisition protocol and analysed immediately after the acquisition in the cath-lab. all aortograms will also be analysed off-line by an independent core laboratory in the netherlands (cardialysis, rotterdam, the netherlands). the primary endpoint of the study is the feasibility of the on-line assessment of regurgitation (percentage of analysable cases). the secondary endpoint is the reproducibility of results between the on-line assessment and the off-line analysis by the independent core laboratory.

Eligibility criteria:
inclusion criteria: * consecutive patients with indication to undergo tavr by the institution's heart team. exclusion criteria: * patients that were not considered by the institution's heart team as eligible
autologous bone marrow stem cells in middle cerebral artery acute stroke treatment.

Conditions: Stroke, Acute; Infarction, Middle Cerebral Artery

Summary: the aim of the study is to determine the safety and efficacy on an autologous cd34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute middle cerebral artery stroke.

the proposed trial will involve the recruitment of a total of 20 patients. the cells will be collected from ten subject recruited as cases, via bone marrow sampling. the aspirate will be centrifuged on a ficoll density gradient to isolate mononuclear cells, which will be resuspended in heparinized isotonic saline for infusion into the area of the stroke intra-arterially using the middle cerebral artery. the investigators will monitor each case and control for a period of 6 months post-stem cell infusion. initially, they will be subjected to a review after one month,three months and finally 6 months. assessment of adverse events will be by physical examination and measurement of laboratory parameters. assessment of efficacy will be by physical examination and the measurement of laboratory, ct and mri parameters.

Eligibility criteria:
inclusion criteria: * symptoms and signs of clinically definite middle cerebral artery acute stroke. * time of stroke onset is known and treatment can be started between day 5 and 9 of onset. * dwi-mri has reliably shown relevant acute ischemic lesions * extracranial duplex/transcranial doppler must confirm intra/extracranial arteries permeability. * the stroke is severe (nih stroke scale \>= 8 before procedure). * an age range of 18-80 years old. exclusion criteria: * patients out of inclusion age range. * lacunar infarction. * patients with cancer. * patients with present or previous malignant disease during the last 5 years, except for basal cell carcinoma. * hematological causes of stroke. * severe co-morbidity. * hepatic or renal dysfunction. * the patient is female and of childbearing potential (unless it is certain that pregnancy is not possible) or breast feeding. * patient is likely to be unavailable for follow-up. * patient with evidence of life threatening infection of life threatening illness. * patient was already dependent in activities of daily living before the present acute stroke.
study of abatacept (bms-188667) in subjects with active rheumatoid arthritis on background non-biologic dmards (disease modifying antirheumatic drugs) who have an inadequate response to anti-tnf therapy

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (dmards) approved for rheumatoid arthritis (ra) in subjects with active ra. secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.


Eligibility criteria:
inclusion criteria: * completed double-blind portion of the im101064 study. * rheumatoid arthritis (ra) for greater than 1 year from the time of initial diagnosis * american college of rheumatology (acr) functional class i, ii, iii * subjects currently or previously received an anti-tnf therapy at an approved labeled dose for at least 3 months exclusion criteria: * subjects with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules) * history of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection)
outpatient chest tube management following thoracic resection improves patient length of stay and satisfaction without compromising outcomes

Conditions: Lung Cancer; Pneumothorax; Subcutaneous Emphysema

Summary: discharging patients home with air leak and chest tube to portable drainage device after thoracic resection is cost effective and safe without compromising patients outcome or satisfaction. despite good outcomes this practice is not done universally by thoracic surgeons.

medical chart database to identify patients ,of one thoracic surgeon over the last seven years, who underwent thoracic resection and were discharged home with an air leak and chest tube to portable drainage device was completed. once all patients were identified, all possible vulnerable patients were discarded. written consent for participation was obtained by eligible patients and subjects willing to participate were given further explanation of the study. all willing participants completed an outpatient chest tube quality of life questionnaire. upon completion of the questionnaire participants involvement in the study was complete. data was collected and correlations between variables statistically analysed to determine significant factors affecting care.

Eligibility criteria:
inclusion criteria: * all patients 18-89, * all genders, * all patients undergoing thoracic resection, * all patients discharged with chest tube exclusion criteria: * minors, * all patients \> 90 years old, * all mentally challenged, * all non-english speaking patients
evaluation of the effectiveness of secukinumab in patients with moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: this study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the dermatology clinics of the 14 university, training \& research hospitals in turkey. data were extracted between 02 september 2020 and 29 april 2021.

the study was a retrospective, multicenter, cohort study which was based on data collection at week 4,16 and 52 of secukinumab treatment of moderate to severe plaque psoriasis. the observational design of the study allowed data collection about secukinumab treatment patterns and clinical and demographic characteristics of plaque psoriasis patients treated with secukinumab for 52 weeks in turkey. the adults included in the study were treated with secukinumab for 52 weeks. the adults with no available data of pasi scores at specific time points (4, 16 and 52 weeks) and no definite description of treatment cessation were excluded. the study population consisted of adults treated with secukinumab for 52 weeks and adults dropped out before 52 weeks with available data of pasi scores at 4, 16 and 52 weeks and definite description of treatment cessation. retrospective data collection from secondary sources (hospital medical records) allowed time and cost saving since description of patients' characteristics, analyses of outcomes of interest and their determinants could be made in a short period of time. the study consisted of the following periods: * the index date was the date of initiation of secukinumab * the study (index) period was between 18 may 2018 to 31 may 2020 * the follow-up (post-index) period was 4,16 and 52 weeks post-index

Eligibility criteria:
inclusion criteria: * a diagnosis of psoriasis * age ≥ 18 years at registry baseline. * patients with a firm diagnosis of chronic plaque psoriasis for at least 6 months before enrollment * secukinumab treatment should be initiated 52 weeks before data collection date * moderate to severe plaque psoriasis with pasi score of ≥10 before initiating secukinumab. exclusion criteria: * patients diagnosed with others types of psoriasis (pustular psoriasis, erythrodermic psoriasis etc) are excluded. * previous exposure to secukinumab or any other biologic drug directly targeting il-17a or il-17ra

Keywords: secukinumab, real life, pasi, effectiveness, anti-il17
determining molecular drivers of radiation dermatitis

Conditions: Breast Cancer

Summary: this study is being conducted to address key gaps in current knowledge and set the stage for rational design of strategies to prevent (pre-exposure to radiation), mitigate (post-exposure to radiation before overt signs/symptoms appear), and/or treat (post-onset of signs/symptoms) radiation dermatitis (itchy, dry skin or a rash on swollen, reddened skin).


Eligibility criteria:
inclusion criteria: * patients receiving standard-of-care postoperative radiation therapy (2-2.7 gy per fraction) to the breast and/or chest wall for breast cancer treatment. * tissue diagnosis of breast cancer. * age \> 18 years * signed informed consent. * complete blood count within normal limits within the preceding 2 weeks. exclusion criteria: * induction chemotherapy or biologic therapy * concurrent chemotherapy or biologic therapy * autoimmune disease with skin manifestations - psoriasis, dermatomyositis, scleroderma, eczema, polymyositis * allergy to lidocaine anesthesia * known bleeding diathesis (anticoagulation with warfarin, coagulation/bleeding disorders, vitamin c or k deficiency, thrombocytopenia) * history of keloids or easy scarring
treatment effects inclusive cognitive impact and possibilities to individually adjusted treatment in patients with intracranial tumors with clinical, neuropsychological and imaging parameters

Conditions: Intracranial Tumor

Summary: the main purposes with this trial is to investigate the potential of mri with diffusion and blood volume, flow in brain to diagnose and to measure treatment effects in patients with intracranial tumors, especially gliomas and metastases in a prospective trial, to evaluate the possibilities to individually adjusted treatment in this category of patients depending on treatment outcomes measured by mri, to perform clinical follow up in connection with mri to evaluate a correlation and to perform testing of cognitive ability before, during, and after treatment and to investigate if given treatment causes any decrease in the patients habitual state.


Eligibility criteria:
inclusion criteria: * age 18 years or older * suspected primary brain tumor, verified glioblastoma or non surgically treated metastases from solid tumor * increasing mri changes in patients with previous verified glioblastoma * be able to speak swedish without difficulties (because of the neuropsychological investigations) * written informed concent exclusion criteria: * unability to perform mri

Keywords: glioma brain tumors brain metastases mri cognitive measurement neuropsychological evaluation dw-mri p-mri mrs
transcutaneous oximetry, transcutaneous carbon dioxide and supplemental oxygen therapy in lower limb amputations

Conditions: Amputation Wound

Summary: tcom is a multicentre prospective cohort study in patients undergoing lower limb amputations. patients will provide oxygen and carbon dioxide measurements in the lower limb for 20 to 30 minutes before their surgery and will be followed up until 6 months after their surgery. the purpose of the tcom study is to determine the ability of oxygen and carbon dioxide measurements in the legs of patients undergoing lower limb amputation to predict wound healing complications and to determine an optimum cutoff value for both oxygen and carbon dioxide levels beyond which healing complications are likely to occur and a closer amputation level is indicated.

lower limb amputation is a serious and unfortunate outcome for many patients with vascular disease, especially those with diabetes. it results in significant decreases in all aspects of quality of life. the need for further surgery to revise the amputation to a more proximal level leads to increased potential for serious and life-threatening complications, as well as a decrease in patient morale. from surveys and background literature, it can be estimated that there are approximately 8600 vascular disease-related lower limb amputations in canada each year. as the epidemic of diabetes continues to unfold and the mean age of the population increases, this number is expected to increase. the results of this study may significantly assist in the surgical and clinical care of this patient population by providing clinicians with a means to assess appropriate lower limb amputation levels. further, the modalities of transcutaneous measures may assist in guiding further intervention studies in higher risk patients to improve clinically important outcomes. this study will act in part as a feasibility trial for a randomized controlled trial assessing the efficacy of supplemental oxygen therapy, including hyperbaric oxygen therapy, as a therapeutic tool to increase rates of healing after lower limb amputation.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. requires a lower limb amputation between the ankle and knee due to vascular complications 3. provides written informed consent exclusion criteria: 1. requires a lower limb amputation for non-vascular reasons, including trauma and cancer 2. requires primary amputation below the level of the ankle or above the knee

Keywords: transcutaneous oximetry transcutaneous carbon dioxide leg amputation wound healing failure amputation revision